Subscribe free

Sarcoma & rare tumors ·

PRRT enhances survival in patients after GEP-NET progression

Peptide receptor radionuclide therapy (PRRT) significantly improves progression-free survival (PFS) and overall survival (OS) in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who progress after surgical resection. Among 237 analyzed patients, those receiving PRRT experienced a median PFS of 32.4 months compared to 11.0 months for those who did not (p < 0.001). Median OS was also longer at 49.8 months versus 38.4 months (p = 0.009), supporting PRRT as a beneficial treatment approach.

Journal Article by Borbon LC, Sherman SK (…) Howe JR et 9 al. in Ann Surg Oncol

© 2024. Society of Surgical Oncology.

read the whole article in Ann Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Sarcoma & rare tumors.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Sarcoma & rare tumors

The latest stitches

Ann Surg Oncol26 Oct 2026

SSTR PET finds more distant disease in GEP-NETs

In this 24-year surgical cohort, SSTR PET identified bone and retroperitoneal nodal metastases more often than Octreoscan—findings that may matter for operative planning.

Ann Surg Oncol11 May 2026

Mapping Surgical Evidence for GEP-NETs

Surgical management of gastro-entero-pancreatic neuroendocrine tumors is inconsistent, highlighting the need for clearer guidelines.

All papers in Sarcoma & rare tumors →